Canadian drugmaker Valeant Pharmaceuticals said it will increase the list prices of products in its neurology, gastro-intestinal and urology portfolios by 2 percent to 9 percent.
These planned wholesale acquisition price changes are effective Oct. 14, Valeant said on Friday.
U.S.-traded shares of Valeant were down more than 1.6 percent Friday afternoon.
Shares of the Laval, Quebec-based company were down 2.4 percent on the Toronto Stock Exchange.